Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
368
resultados
Última actualización
02/11/2026 [10:35:00]
Resultados 200 a 225 de 368
Resumen de: US20260287601A1
A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.
Resumen de: US20260287578A1
The anatomical model of a nasal cavity, such as a human nasal cavity, for in-vitro inhalation studies such as toxicological screening, intranasal drug delivery studies, and neurophysiological studies. The model includes a model body including separable upper and lower model portions together defining the nasal cavity and including fluidic channels therein that define an olfactory region of the upper model portion, and a nasal passage defined in the lower model portion. A biocompatible porous membrane is positioned between the upper and lower model portions, and the biocompatible membrane is configured for culturing olfactory epithelium cells thereon. An artificial mucous layer coats a surface of the nasal cavity and is configured to collect particles passing through the nasal cavity.
Resumen de: US20260289785A1
0000 The present disclosure describes a method of quantifying analyte levels using gold nanoparticles. The present disclosure also describes a device to quantify analyte levels using gold nanoparticles and image processing of pixels isolated from a single vector. The methods, devices, and systems of the disclosure can be used to quantify analytes such as luteinizing hormone, progesterone, estradiol, or testosterone.
Resumen de: US20260285898A1
The present application relates to compounds based on a triterpene glycoside saponin scaffold, which bear an acyl chain comprising a photoreactive moiety and a terminal biotin, of general formula (I)The present application also relates to the use of said compounds and compositions thereof in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers as well as its use as chemical probe in photoaffinity labeling (PAL) (for photocrosslinking with interacting partners) followed by affinity purification of the covalent complex and MS-based proteomics for target identification and elucidation of the protein receptor.
Resumen de: US20260287581A1
0000 The present disclosure relates to a method for estimating the amount of a tau protein accumulated in the brain. One of a capture antibody and a detection antibody which are used in the method is an antibody which recognizes an amino acid sequence in a middle part of a phosphorylated tau protein, and the other is an antibody which recognizes a phosphorylated epitope including a phosphorylated amino acid residue of the phosphorylated tau protein.
Resumen de: US20260286293A1
Disclosed herein are pluripotent stem cells cultured with one or more peptide and methods of isolating said stem cells. Also disclosed are methods of targeting the stem cells to a desired region or area within an organism. Also disclosed are methods of using the isolated stem cells for the improvement of fertility, for the promotion of hair growth, for the treatment or prevention of skin conditions, for the treatment or improvement of bone disorders, for the treatment of malignancies, and for the treatment of neurological disorders.
Resumen de: US20260287585A1
Detecting a binding event of specific binding pair-forming substances, comprising includes: providing a layer of a first specific binding pair-forming substance (SBPS) on a substrate, providing an enclosure of the layer with a first dielectric medium (DM) rinsing the enclosure for a first time period with a second DM, restoring the first DM in the enclosure following the rinsing, feeding a solution of a second SBPS to the enclosure to cause an interaction between the first second SBPS following the restoring, incubating the enclosure for a second time period, the interaction including a binding event when the first and second SBPS provide a specific binding pair, detecting a shift in a parameter representative of a layer dielectric function following the incubating, comparing the shift with a threshold, whereby when the shift exceeds the threshold the binding event has occurred.
Resumen de: US20260287598A1
0000 A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.
Resumen de: US20260287599A1
Embodiments of the present disclosure pertain to methods of assessing pain in a subject by receiving one or more measured levels of glycine receptors of the subject; and correlating differentially expressed levels of the glycine receptors to pain. The methods of the present disclosure may also include a step of implementing a treatment decision based on the assessment. In some embodiments, the methods of the present disclosure may be repeated after implementing the treatment decision. Additional embodiments of the present disclosure pertain to systems for assessing pain in a subject. In some embodiments, the systems include computer-readable storage mediums with program codes that implement the methods of the present disclosure.
Resumen de: US20260284227A1
The present invention provides a method for providing modified mRNAs of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.
Resumen de: US20260285956A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260285954A1
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.
Resumen de: US20260286363A1
0000 The present disclosure provides compositions and methods of identifying, making, and using the same for the prevention and treatment of lysosomal storage diseases. Provided are also compositions and methods of diagnosing lysosomal storage diseases.
Resumen de: WO2026198531A2
The present disclosure provides a method for identifying a tumor specific small peptide that binds specifically to a CDR of an anti-tumor reactive T cell receptor (TCR) isolated from effective anti-tumor T cells and for identifying small peptides that bind specifically to the TCR. It further provides a tumor vaccine comprising an immunogenic amount of the identified tumor-specific neoantigen and formulations comprising a population of lipid nanoparticles (LNP) comprising a nucleic acid payload that encodes the tumor-specific antigen.
Resumen de: CN122790090A
0001 本发明涉及生物技术领域，具体涉及抗BD‑Tau蛋白单克隆抗体或其抗原结合片段及其应用。本发明提供的抗体对BD‑Tau蛋白具有高亲和力，能够特异性识别和结合BD‑Tau蛋白，可用于制备BD‑Tau检测试剂或试剂盒，在阿尔茨海默病的早期筛查和诊断中具有重要的应用价值。
Resumen de: CN122794000A
本发明属于生物技术领域，具体涉及一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用。本发明一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用，诊断产品是以所述多肽或其特异性结合分子为靶分子的检测试剂盒、抗体芯片、抗体探针或检测仪。本发明克服了现有CSF‑TRUST敏感性低、常规指标特异性差的技术问题，且这种多肽标志物能够准确区分神经梅毒患者与非神经梅毒。
Resumen de: CN122790086A
0001 本发明公开了一种检测tau蛋白的抗体及其应用，涉及抗体领域。本发明公开的检测tau蛋白的抗体包括重链互补决定区和轻链互补决定区，该抗体为tau蛋白的检测提供了重要的原料来源，基于该抗体的检测，灵敏度高、特异性强，有助于阿尔茨海默病等相关疾病的预测、诊断、动态监测及预后评估，具有非常高的临床应用价值。
Resumen de: US2019227064A1
0001 The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Resumen de: AU2025211997A1
Provided are an anti-albumin antibody or an antigen-binding fragment thereof and the use thereof, and an anti-albumin nanobody with improved affinity or an antigen-binding fragment thereof. The anti-albumin antibodies or antigen-binding fragments thereof can bind to albumins from different species with high affinity. In addition, the anti-albumin antibody can be linked to a bioactive effector molecule to form a fusion construct without affecting the activity of the bioactive effector molecule.
Resumen de: CN122768451A
0001 本发明属于神经退行性疾病治疗技术领域，具体涉及通过调控神经元Sortilin‑1（SORT1）蛋白的表达或功能活性，预防、治疗阿尔茨海默病（Alzheimer's Disease,·AD）的方法与药物组合物；同时涉及调控神经元‑小胶质细胞信号通路，维持神经元内体稳态、抑制小胶质细胞异常促炎活化、减轻神经炎症、保护神经元功能的技术方案。
Resumen de: KR20260138113A
본 발명은 단백질의 초기 응집 거동을 관찰할 수 있는 단백질의 응집 거동 관찰 장치 및 이를 이용한 단백질의 응집 거동 관찰 방법에 관한 것이다.
Resumen de: CN122772105A
发明公开了一种抗人Aβ40的抗体及其应用。所述抗体含重链可变区VH和轻链可变区VL；所述VH包含HCDR1、HCDR2和HCDR3，所述VL包含LCDR1、LCDR2和LCDR3；所述HCDR1‑HCDR3分别包含如SEQ ID NO:1‑3所示的氨基酸序列，所述LCDR1‑LCDR3分别包含如SEQ ID NO:4‑6所示的氨基酸序列。本发明的抗体灵敏性高、特异性好，基于该抗体对人Aβ40进行免疫检测，操作简单、灵敏度高、特异性强，可实现人Aβ40的快速检测，对评估人Aβ40具有重要意义。
Resumen de: CN122775828A
0001 本发明公开一种用于加工黄精的综合质量评价方法及在制备抗衰老产品中的应用。本发明的方法通过主客观权重协同优化与数据标准化处理构建科学评价模型，采用合适的综合评分法实现了对加工黄精的综合质量评价，进而指导工艺参数优化，同时提升主要活性成分保留率与稳定性，实现质量与效率的双重提升。本发明还进行了加工黄精的提取物在改善衰老动物记忆下降中的功效研究，通过构建的具有阿尔茨海默病特征的动物模型的功效相关研究结果表明，包含黄精粗多糖或黄精粗皂苷的黄精加工产品能够有效改善运动障碍、认知功能障碍和脑区Aβ病理性斑块的蓄积，同时具有显著的脑部细胞凋亡抑制作用。
Resumen de: CN122772974A
本发明涉及生物医药技术领域，尤其是涉及基于SERPING1的PASC相关心血管系统症状风险评估应用。本发明提供了一种以SERPING1为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Nº publicación: CN122775877A 18/09/2026
Solicitante:
安培里翁公司
Resumen de: US2021063416A1
A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
BOPI
Sede Electrónica
